Literature DB >> 28435158

A balancing act between IFITM3 and IRF3.

Temet M McMichael1, Mahesh Chemudupati1, Jacob S Yount2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28435158      PMCID： PMC6207572          DOI： 10.1038/cmi.2017.18

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  14 in total

Review 1.  Dynamic control of type I IFN signalling by an integrated network of negative regulators.

Authors:  Rebecca A Porritt; Paul J Hertzog
Journal:  Trends Immunol       Date:  2015-02-25       Impact factor: 16.687

2.  IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.

Authors:  Charles C Bailey; Guocai Zhong; I-Chueh Huang; Michael Farzan
Journal:  Annu Rev Virol       Date:  2014-11-01       Impact factor: 10.431

3.  Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3.

Authors:  Jacob S Yount; Bruno Moltedo; Yu-Ying Yang; Guillaume Charron; Thomas M Moran; Carolina B López; Howard C Hang
Journal:  Nat Chem Biol       Date:  2010-07-04       Impact factor: 15.040

4.  Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination.

Authors:  Nicholas M Chesarino; Temet M McMichael; Jocelyn C Hach; Jacob S Yount
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

5.  IFITM3 restricts the morbidity and mortality associated with influenza.

Authors:  Aaron R Everitt; Simon Clare; Thomas Pertel; Sinu P John; Rachael S Wash; Sarah E Smith; Christopher R Chin; Eric M Feeley; Jennifer S Sims; David J Adams; Helen M Wise; Leanne Kane; David Goulding; Paul Digard; Verneri Anttila; J Kenneth Baillie; Tim S Walsh; David A Hume; Aarno Palotie; Yali Xue; Vincenza Colonna; Chris Tyler-Smith; Jake Dunning; Stephen B Gordon; Rosalind L Smyth; Peter J Openshaw; Gordon Dougan; Abraham L Brass; Paul Kellam
Journal:  Nature       Date:  2012-03-25       Impact factor: 49.962

6.  IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.

Authors:  Eric M Feeley; Jennifer S Sims; Sinu P John; Christopher R Chin; Thomas Pertel; Li-Mei Chen; Gaurav D Gaiha; Bethany J Ryan; Ruben O Donis; Stephen J Elledge; Abraham L Brass
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

7.  Ifitm3 limits the severity of acute influenza in mice.

Authors:  Charles C Bailey; I-Chueh Huang; Christina Kam; Michael Farzan
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

8.  IFITM proteins restrict viral membrane hemifusion.

Authors:  Kun Li; Ruben M Markosyan; Yi-Min Zheng; Ottavia Golfetto; Brittani Bungart; Minghua Li; Shilei Ding; Yuxian He; Chen Liang; James C Lee; Enrico Gratton; Fredric S Cohen; Shan-Lu Liu
Journal:  PLoS Pathog       Date:  2013-01-24       Impact factor: 6.823

9.  IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion.

Authors:  Tanay M Desai; Mariana Marin; Christopher R Chin; George Savidis; Abraham L Brass; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

10.  IFITM3 inhibits virus-triggered induction of type I interferon by mediating autophagosome-dependent degradation of IRF3.

Authors:  Li-Qun Jiang; Tian Xia; Yun-Hong Hu; Ming-Shun Sun; Shuang Yan; Cao-Qi Lei; Hong-Bing Shu; Ji-Hua Guo; Yu Liu
Journal:  Cell Mol Immunol       Date:  2017-04-24       Impact factor: 11.530
View more
  2 in total

Review 1.  More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins.

Authors:  Guoli Shi; Olivier Schwartz; Alex A Compton
Journal:  Retrovirology       Date:  2017-11-21       Impact factor: 4.602

2.  mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3.

Authors:  Guoli Shi; Stosh Ozog; Bruce E Torbett; Alex A Compton
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.